Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 717

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial

Open access
Mitzner, Steffen R., Stange, Jan, Klammt, Sebastian, Risler, Teut, Erley, Christiane M., Bader, Brigitte D., Berger, Elke D., Lauchart, Werner, Peszynski, Piotr, Freytag, Jens, Hickstein, Heiko, Loock, Jan, Löhr, Johannes-Mathias, Liebe, Stefan, Emmrich, Jörg, Korten, Gero, Schmidt, Reinhard · 2000 · Liver Transplantation

Abstract

In hepatorenal syndrome (HRS), renal insufficiency is often progressive, and the prognosis is extremely poor under standard medical therapy. The molecular adsorbent recirculating system (MARS) is a modified dialysis method using an albumin-containing dialysate that is recirculated and perfused online through charcoal and anion-exchanger columns. MARS enables the selective removal of albumin-bound substances. A prospective controlled trial was performed to determine the effect of MARS treatment on 30-day survival in patients with type I HRS at high risk (bilirubin level, ≥15 mg/dL) compared with standard treatment. Thirteen patients with cirrhosis with type I HRS were included from 1997 to 1999. All were Child’s class C, with Child-Turcotte-Pugh scores of 12.4 ± 1.0, United Network for Organ Sharing status 2A, and total bilirubin values of 25.7 ± 14.0 mg/dL. Eight patients were treated with the MARS method in addition to hemodiafiltration (HDF) and standard medical therapy, and 5 patients were in the control group (HDF and standard medical treatment alone). None of these patients underwent liver transplantation or received a transjugular intrahepatic portosystemic shunt or vasopressin analogues during the observation period. In the MARS group, 5.2 ± 3.6 treatments (range, 1 to 10 treatments) were performed for 6 to 8 hours daily per patient. A significant decrease in bilirubin and creatinine levels (P< .01) and increase in serum sodium level and prothrombin activity (P< .01) were observed in the MARS group. Mortality rates were 100% in the control group at day 7 and 62.5% in the MARS group at day 7 and 75% at day 30, respectively (P< .01). We conclude that the removal of albumin-bound substances with the MARS method can contribute to the treatment of type I HRS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/lt.500060326

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 18

  1. Arroyo, 1992, Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis, Gastroenterology, 102, 1077, 10.1016/0016-5085(92)90203-B · doi:10.1016/0016-5085(92)90203-b
  2. Earley, 1979, Hepatorenal syndrome, 495
  3. Epstein, 1997, Hepatorenal syndrome: Emerging perspectives, Semin Nephrol, 17, 563
  4. Gentilini, 1999, Hepatorenal syndrome and its treatment today, Eur J Gastroenterol Hepatol, 11, 1061, 10.1097/00042737-199909000-00021 · doi:10.1097/00042737-199909000-00021
  5. Eckardt, 1999, Renal failure in liver disease, Intensive Care Med, 25, 5, 10.1007/s001340050780 · doi:10.1007/s001340050780
  6. Brensing, 1999, Treatment of liver disease, 53
  7. Gulberg, 1998, Successful conservative therapy of hepatorenal syndrome with vasopressin I receptor antagonist ornipressin, Z Gastroenterol, 36, 1053
  8. Ganne-Carrie, 1996, Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation, Dig Dis Sci, 41, 1054
  9. Gulberg, 1999, Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine, Hepatology, 30, 870, 10.1002/hep.510300430 · doi:10.1002/hep.510300430
  10. Hadengue, 1998, Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome, J Hepatol, 29, 565, 10.1016/S0168-8278(98)80151-7 · doi:10.1016/s0168-8278(98)80151-7
  11. Kaplan, 1997, Extracorporeal blood purification in the management of patients with hepatic failure, Semin Nephrol, 17, 576
  12. Hughes, 1997, Acute liver failure, 278
  13. Awad, 1997, Characteristics of an albumin dialysate hemodiafiltration system for the clearance of unconjugated bilirubin, ASAIO J, 43, M745, 10.1097/00002480-199703000-00056 · doi:10.1097/00002480-199703000-00056
  14. Kreymann, 1999, Albumin dialysis: Effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein-bound toxins, J Hepatol, 31, 1080, 10.1016/S0168-8278(99)80322-5 · doi:10.1016/s0168-8278(99)80322-5
  15. Mitzner, 1999, Albumin dialysis “MARS.” Clinical results in extracorporeal treatment of hepatorenal syndrome [abstract], Hepatology, 30, S418A
  16. Awad, 1999, Can the clearance of tumor necrosis factor-alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system?, ASAIO J, 45, 47, 10.1097/00002480-199901000-00011 · doi:10.1097/00002480-199901000-00011
  17. Loock, 1997, Change of human serum amino acid patterns (Fischer index) during a new dialysis treatment for liver failure (MARS) [abstract], Int J Artif Organs, 20, 500A
  18. Perez, 1996, The kidney in liver diseaseed 4, 517

Cited by

See all 717

Metadata

Authors
Mitzner, S. R., Stange, J., Klammt, S., Risler, T., Erley, C. M., Bader, B. D., Berger, E. D., Lauchart, W., Peszynski, P., Freytag, J., Hickstein, H., Loock, J., Löhr, J.-M., Liebe, S., Emmrich, J., Korten, G., & Schmidt, R.
Venue
Liver Transplantation
Published
2000-05
Volume
6
Issue
3
Pages
277-286
ISSN
1527-6465 (ISSN-L)
OpenAlex
W2073024831
Cited by
717
References
20
FWCI
28.49
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 5601 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.